Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efsubaglutide Alfa in Overweight or Obesity
NCT06732960Phase 2Completed
- Sponsor
- Shanghai Innogen Pharmaceutical Technology Co., Ltd.
- Start
- Apr 2024
- Primary completion
- Nov 2024
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of efsubaglutide alfa in obesity and Overweight (5 arms), sponsored by Shanghai Innogen Pharmaceutical Technology Co., Ltd. Primary endpoints: Change in Body Weight and Adverse Events. Started Apr 2024; status: completed.
02
Drugs
efsubaglutide alfa
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06732960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06732960.